TWI859506B - 化合物組合用於製作血管疾病治療藥的用途 - Google Patents
化合物組合用於製作血管疾病治療藥的用途 Download PDFInfo
- Publication number
- TWI859506B TWI859506B TW111104639A TW111104639A TWI859506B TW I859506 B TWI859506 B TW I859506B TW 111104639 A TW111104639 A TW 111104639A TW 111104639 A TW111104639 A TW 111104639A TW I859506 B TWI859506 B TW I859506B
- Authority
- TW
- Taiwan
- Prior art keywords
- sildenafil
- vascular
- compound combination
- treatment
- sild
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 208000019553 vascular disease Diseases 0.000 title claims abstract description 19
- 229940126585 therapeutic drug Drugs 0.000 title description 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 178
- 229960003310 sildenafil Drugs 0.000 claims abstract description 89
- 239000003814 drug Substances 0.000 claims abstract description 42
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 31
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 31
- 239000004475 Arginine Substances 0.000 claims abstract description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 17
- 229960003121 arginine Drugs 0.000 claims abstract description 17
- 230000002792 vascular Effects 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 8
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000001147 pulmonary artery Anatomy 0.000 claims description 3
- 208000008445 altitude sickness Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 41
- 238000011282 treatment Methods 0.000 description 52
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 25
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 16
- 210000003556 vascular endothelial cell Anatomy 0.000 description 16
- 235000009697 arginine Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000008728 vascular permeability Effects 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000036632 reaction speed Effects 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 2
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
| AU2023219232A AU2023219232A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| US18/836,532 US20250134892A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| JP2024547249A JP2025504219A (ja) | 2022-02-09 | 2023-02-09 | Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ |
| KR1020247028842A KR20240146018A (ko) | 2022-02-09 | 2023-02-09 | Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 |
| PCT/GB2023/050296 WO2023152500A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| CN202310100652.1A CN116808224A (zh) | 2022-02-09 | 2023-02-09 | 用于治疗血管疾病的化合物组合 |
| EP23706081.9A EP4475833A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202332450A TW202332450A (zh) | 2023-08-16 |
| TWI859506B true TWI859506B (zh) | 2024-10-21 |
Family
ID=85283927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134892A1 (https=) |
| EP (1) | EP4475833A1 (https=) |
| JP (1) | JP2025504219A (https=) |
| KR (1) | KR20240146018A (https=) |
| CN (1) | CN116808224A (https=) |
| AU (1) | AU2023219232A1 (https=) |
| TW (1) | TWI859506B (https=) |
| WO (1) | WO2023152500A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025046207A1 (en) * | 2023-08-31 | 2025-03-06 | Future Pharmtech Inc. | New use of a pde 5 inhibitor combination in promoting neurite outgrowth |
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000000212A1 (en) | 1998-06-26 | 2000-01-06 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL132460A0 (en) * | 1999-10-19 | 2001-03-19 | Laniado Shlomo | Sildenafil preparation |
-
2022
- 2022-02-09 TW TW111104639A patent/TWI859506B/zh active
-
2023
- 2023-02-09 AU AU2023219232A patent/AU2023219232A1/en active Pending
- 2023-02-09 CN CN202310100652.1A patent/CN116808224A/zh active Pending
- 2023-02-09 KR KR1020247028842A patent/KR20240146018A/ko active Pending
- 2023-02-09 US US18/836,532 patent/US20250134892A1/en active Pending
- 2023-02-09 EP EP23706081.9A patent/EP4475833A1/en active Pending
- 2023-02-09 WO PCT/GB2023/050296 patent/WO2023152500A1/en not_active Ceased
- 2023-02-09 JP JP2024547249A patent/JP2025504219A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000000212A1 (en) | 1998-06-26 | 2000-01-06 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Ruipeng Zhang,et al "N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway", Clin Exp Pharmacol Physiol, 46(2): 163-172, 2019 Feb. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116808224A (zh) | 2023-09-29 |
| JP2025504219A (ja) | 2025-02-06 |
| US20250134892A1 (en) | 2025-05-01 |
| TW202332450A (zh) | 2023-08-16 |
| AU2023219232A1 (en) | 2024-07-25 |
| WO2023152500A1 (en) | 2023-08-17 |
| EP4475833A1 (en) | 2024-12-18 |
| KR20240146018A (ko) | 2024-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI859506B (zh) | 化合物組合用於製作血管疾病治療藥的用途 | |
| Bywaters et al. | Crush injuries with impairment of renal function | |
| Sánchez-Lozada et al. | Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia | |
| Mehanna et al. | An optimized dose of raspberry ketones controls hyperlipidemia and insulin resistance in male obese rats: Effect on adipose tissue expression of adipocytokines and Aquaporin 7 | |
| JP2001526658A (ja) | 虚血の治療および／または予防を行う際の医薬組成物の使用 | |
| Vavrinec et al. | Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat | |
| Dinc et al. | Methylene blue inhibits the inflammatory process of the acetic acid-induced colitis in rat colonic mucosa | |
| Zhang et al. | GSK-3β inhibition elicits a neuroprotection by restoring lysosomal dysfunction in neurons via facilitation of TFEB nuclear translocation after ischemic stroke | |
| Benigni et al. | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model | |
| Hedayati et al. | Growth hormone–releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells | |
| Gong et al. | Endothelium-dependent relaxation effects of actinidia arguta extracts in coronary artery: Involvement of enos/akt pathway | |
| Mendel et al. | Pharmacology management in improving exercise capacity of patients with Fontan circulation: a systematic review and meta-analysis | |
| Kumar et al. | Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial | |
| Ding et al. | The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway | |
| Liu et al. | Protective effect of crocin on liver function and survival in rats with traumatic hemorrhagic shock | |
| JP2020525511A (ja) | 低濃度のキセノンおよびアルゴンを含有するガス混合物は血栓溶解剤の触媒活性を阻害することなく神経保護を提供する | |
| Ko et al. | Therapeutic hypothermia protects against heat stroke-induced arterial hypotension via promoting left ventricular performance in rats | |
| CN118806777B (zh) | 水苏糖在制备预防和缓解心肌缺血再灌注损伤药物中的应用 | |
| Gruber et al. | Protracted metabolic acidosis: the impact of acute ethanol in hemorrhagic shock | |
| CN115944693A (zh) | 一种薏苡附子散保护缺血心肌作用机制的研究方法 | |
| Loeven et al. | Elastolytic Enzymes and Elastin in the Aging Rat: I. Pancreatic Elastolytic Enzymes | |
| Harada et al. | Role of neutrophil elastase in development of pulmonary vascular injury and septic shock in rats | |
| TWI907160B (zh) | 具有護腎功效的咪唑二肽組合物及其應用 | |
| Yu et al. | Protective Effect of Sufentanil against Myocardial Ischemia Reperfusion Injury in Rats | |
| Liu et al. | Cavernosum smooth muscle relaxation induced by Schisandrol A via the NO-cGMP signaling pathway |